Dr. Omid Hamid on the Possibility of Triplet Trials in Melanoma

Omid Hamid, MD

Hamid says the future will hold adding more tolerable regimens in to the treatment paradigm of melanoma, based on the past success of the treatments already utilized and approved.

Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses the possibilities of triplet trials in the next few years in melanoma. Hamid says the future will hold adding more tolerable regimens in to the treatment paradigm of melanoma, based on the past success of the treatments already utilized and approved.